This page shows the latest REGN5458 news and features for those working in and with pharma, biotech and healthcare.
Other drugs making their way through development include bispecific antibodies from Amgen ( AMG 420), Regeneron (REGN5458) and Bluebird Bio/Bristol-Myers Squibb (CC-92369), as well as ADCs from AstraZeneca (MEDI2228)
Regeneron has made its first appearance on the BCMA scene, revealing data for its bispecific antibody candidate REGN5458 in multiple myeloma. . ... The much anticipated first results from the first two dose groups in the phase 1/2 trial of REGN5458 were
The two candidates selected as most promising are REGN5458 (aka BCMAxCD3), a BCMA and CD3 targeting bispecific antibody and REGN4018, a MUC16 and CD3 targeting bispecific antibody.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.